1 January 2025 false No description of principal activity Taxfiler 2024.6 13786953business:PrivateLimitedCompanyLtd2025-01-012025-12-31 137869532024-12-31 137869532025-01-012025-12-31 13786953business:AuditExemptWithAccountantsReport2025-01-012025-12-31 13786953business:FilletedAccounts2025-01-012025-12-31 137869532025-12-31 13786953business:Director12025-01-012025-12-31 13786953business:Director22025-01-012025-12-31 13786953business:RegisteredOffice2025-01-012025-12-31 137869532024-12-31 13786953core:WithinOneYear2025-12-31 13786953core:WithinOneYear2024-12-31 13786953core:ShareCapitalcore:PreviouslyStatedAmount2025-12-31 13786953core:ShareCapitalcore:PreviouslyStatedAmount2024-12-31 13786953core:SharePremiumcore:PreviouslyStatedAmount2025-12-31 13786953core:SharePremiumcore:PreviouslyStatedAmount2024-12-31 13786953core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2025-12-31 13786953core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2024-12-31 13786953core:PreviouslyStatedAmount2025-12-31 13786953core:PreviouslyStatedAmount2024-12-31 13786953business:SmallEntities2025-01-012025-12-31 13786953countries:EnglandWales2025-01-012025-12-31 13786953core:FurnitureFittings2025-01-012025-12-31 13786953core:ComputerEquipment2025-01-012025-12-31 13786953core:Goodwill2024-12-31 13786953core:Goodwill2025-12-31 13786953core:Goodwill2025-01-012025-12-31 13786953core:LandBuildings2024-12-31 13786953core:FurnitureFittings2024-12-31 13786953core:ComputerEquipment2024-12-31 13786953core:LandBuildings2025-01-012025-12-31 13786953core:LandBuildings2025-12-31 13786953core:FurnitureFittings2025-12-31 13786953core:ComputerEquipment2025-12-31 137869532024-01-012024-12-31 iso4217:GBP xbrli:pure
Company Registration No. 13786953 (England and Wales)
G. Lowe Pharma Limited Unaudited accounts for the year ended 31 December 2025
G. Lowe Pharma Limited Unaudited accounts Contents
Page
Company information
3
Statement of financial position
4
Notes to the accounts
5
- 2 -
G. Lowe Pharma Limited Company Information for the year ended 31 December 2025
Directors
Mr S R Raja Mr J S Raja
Company Number
13786953 (England and Wales)
Registered Office
G Lowe Chemist 203 East Lane Wembley Middlesex HA0 3NG England
Accountants
Infinity Accountants 27 Coniston Gardens Pinner Middlesex HA5 2JN
- 3 -
G. Lowe Pharma Limited Statement of financial position as at 31 December 2025
2025 
2024 
Notes
£ 
£ 
Fixed assets
Intangible assets
4
688,000 
774,000 
Tangible assets
5
371,819 
379,069 
1,059,819 
1,153,069 
Current assets
Inventories
40,830 
49,800 
Debtors
6
181,929 
120,966 
Cash at bank and in hand
237,214 
114,980 
459,973 
285,746 
Creditors: amounts falling due within one year
7
(208,356)
(169,336)
Net current assets
251,617 
116,410 
Net assets
1,311,436 
1,269,479 
Capital and reserves
Called up share capital
100 
100 
Share premium
1,209,900 
1,209,900 
Profit and loss account
101,436 
59,479 
Shareholders' funds
1,311,436 
1,269,479 
For the year ending 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 13 June 2026 and were signed on its behalf by
Mr S R Raja Director Company Registration No. 13786953
- 4 -
G. Lowe Pharma Limited Notes to the Accounts for the year ended 31 December 2025
1
Statutory information
G. Lowe Pharma Limited is a private company, limited by shares, registered in England and Wales, registration number 13786953. The registered office is G Lowe Chemist, 203 East Lane, Wembley, Middlesex, HA0 3NG, England.
2
Compliance with accounting standards
These are the Company's first financial statements prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. The Company previously prepared its financial statements in accordance with FRS 105, The Financial Reporting Standard applicable to the Micro-entities Regime. The date of transition to FRS 102 was 1 January 2024.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. Turnover from the sale of goods is recognised when goods have been delivered to customers such that risks and rewards of ownership have transferred to them.
Goodwill
On transition to FRS 102, goodwill relating to the acquisition of the trade and assets of a business has been recognised as an intangible fixed asset. In accordance with FRS 102, goodwill is being amortised over its estimated useful economic life of 10 years. The comparative figures for the year ended 31 December 2024 have been restated to reflect the amortisation of goodwill.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Fixtures & fittings
15% Reducing balance
Computer equipment
25% Reducing balance
Stock
Stocks have been valued at the lower of cost and estimated selling price less costs to complete and sell.
Pension costs
The company operates a defined contribution scheme for the benefit of its employees. Contributions payable are recognised in the profit and loss account when due.
- 5 -
G. Lowe Pharma Limited Notes to the Accounts for the year ended 31 December 2025
4
Intangible fixed assets
Goodwill 
£ 
Cost
At 1 January 2025
860,000 
At 31 December 2025
860,000 
Amortisation
At 1 January 2025
86,000 
Charge for the year
86,000 
At 31 December 2025
172,000 
Net book value
At 31 December 2025
688,000 
At 31 December 2024
774,000 
5
Tangible fixed assets
Land & buildings 
Fixtures & fittings 
Computer equipment 
Total 
£ 
£ 
£ 
£ 
Cost or valuation
At cost 
At cost 
At cost 
At 1 January 2025
365,065 
13,658 
8,896 
387,619 
Additions
- 
- 
3,177 
3,177 
Disposals
(7,000)
- 
- 
(7,000)
At 31 December 2025
358,065 
13,658 
12,073 
383,796 
Depreciation
At 1 January 2025
- 
4,976 
3,574 
8,550 
Charge for the year
- 
1,302 
2,125 
3,427 
At 31 December 2025
- 
6,278 
5,699 
11,977 
Net book value
At 31 December 2025
358,065 
7,380 
6,374 
371,819 
At 31 December 2024
365,065 
8,682 
5,322 
379,069 
6
Debtors
2025 
2024 
£ 
£ 
Amounts falling due within one year
VAT
33,958 
31,997 
Trade debtors
95,930 
88,455 
Accrued income and prepayments
2,041 
514 
Other debtors
50,000 
- 
181,929 
120,966 
- 6 -
G. Lowe Pharma Limited Notes to the Accounts for the year ended 31 December 2025
7
Creditors: amounts falling due within one year
2025 
2024 
£ 
£ 
Trade creditors
135,562 
128,644 
Taxes and social security
54,037 
17,338 
Other creditors
13,588 
11,795 
Loans from directors
3,719 
1,459 
Accruals
1,450 
10,100 
208,356 
169,336 
8
Transactions with related parties
Other debtors include short term loan granted to DJR Enterprises Ltd. As at the balance sheet date DJR Enterprises Ltd owed £50,000 (2024: Nil) to the company. G. Lowe Pharma Ltd and DJR Enterprises Ltd are related by virtue of having a common director and shareholder.
9
Average number of employees
During the year the average number of employees was 7 (2024: 8).
10
Reconciliations on adoption of FRS 102
Reconciliation of equity
1 January 2024 
31 December 2024 
£ 
£ 
Capital and reserves (as previously stated)
1,374,961 
1,355,479 
Amortisation of goodwill
- 
(86,000)
Capital and reserves (as restated)
1,374,961 
1,269,479 
Reconciliation of profit or loss for the year
31 December 2024 
£ 
Profit for the year (as previously stated)
55,518 
Amortisation of goodwill
(86,000)
Profit for the year (as restated)
(30,482)
Under FRS 105, purchased goodwill was recognised at cost. Upon transition to FRS 102, goodwill of £860,000 is being amortised over its estimated useful economic life of 10 years. The effect of this adjustment was to decrease net assets by £86,000 at 31 December 2024 after charging goodwill amortisation for the year. Profit for the year ended 31 December 2024 decreased by £86,000 as a result of the goodwill amortisation charge.
- 7 -